TY - JOUR
T1 - Discrimination between malignant and benign ovarian tumors by plasma metabolomic profiling using ultra performance liquid chromatography/mass spectrometry
AU - Zhang, Tao
AU - Wu, Xiaoyan
AU - Yin, Mingzhu
AU - Fan, Lijun
AU - Zhang, Haiyu
AU - Zhao, Falin
AU - Zhang, Wang
AU - Ke, Chaofu
AU - Zhang, Guangming
AU - Hou, Yan
AU - Zhou, Xiaohua
AU - Lou, Ge
AU - Li, Kang
N1 - Funding Information:
This work was funded by the National Natural Science Foundation of China (the project number is 81172767 ).
PY - 2012/5/18
Y1 - 2012/5/18
N2 - Background: Discrimination between epithelial ovarian cancer (EOC) and benign ovarian tumor (BOT) has always been difficult in clinical practice. We investigated the application of metabolomics in distinguishing EOC and BOT and tried to discover valuable biomarkers. Methods: Plasma metabolomic profiling was performed using ultra-performance liquid chromatography mass spectrometry (UPLC/MS). Partial least-squares discriminant analysis was employed to classify EOC and BOT, and reveal their metabolic differences. The area under the receiver-operating characteristic curve (AUC) was utilized to evaluate the predictive performance of the metabolic profiles for external validation set. Results: The metabolomic profiles consisting of 535 metabolites revealed a clear separation between EOC and BOT, with AUC of 0.86 for the external validation set. 6 metabolic biomarkers were identified, and the plasma concentrations of the 4 ascertained biomarkers (L-tryptophan, LysoPC(18:3), LysoPC(14:0), and 2-Piperidinone) were lower in EOC patients than those in BOT patients. Among them, tryptophan and LysoPC have been suspected to participate in cancer progression, and 2-Piperidinone might be a novel biomarker for EOC. Conclusions: Metabolomics could be used to discriminate EOC from BOT in clinical practice, and the identified metabolic biomarkers might be important on investigating the biological mechanisms of EOC.
AB - Background: Discrimination between epithelial ovarian cancer (EOC) and benign ovarian tumor (BOT) has always been difficult in clinical practice. We investigated the application of metabolomics in distinguishing EOC and BOT and tried to discover valuable biomarkers. Methods: Plasma metabolomic profiling was performed using ultra-performance liquid chromatography mass spectrometry (UPLC/MS). Partial least-squares discriminant analysis was employed to classify EOC and BOT, and reveal their metabolic differences. The area under the receiver-operating characteristic curve (AUC) was utilized to evaluate the predictive performance of the metabolic profiles for external validation set. Results: The metabolomic profiles consisting of 535 metabolites revealed a clear separation between EOC and BOT, with AUC of 0.86 for the external validation set. 6 metabolic biomarkers were identified, and the plasma concentrations of the 4 ascertained biomarkers (L-tryptophan, LysoPC(18:3), LysoPC(14:0), and 2-Piperidinone) were lower in EOC patients than those in BOT patients. Among them, tryptophan and LysoPC have been suspected to participate in cancer progression, and 2-Piperidinone might be a novel biomarker for EOC. Conclusions: Metabolomics could be used to discriminate EOC from BOT in clinical practice, and the identified metabolic biomarkers might be important on investigating the biological mechanisms of EOC.
KW - Benign ovarian tumor
KW - Epithelial ovarian cancer
KW - Metabolomics
KW - Plasma
KW - UPLC/MS
UR - http://www.scopus.com/inward/record.url?scp=84862814679&partnerID=8YFLogxK
U2 - 10.1016/j.cca.2012.01.026
DO - 10.1016/j.cca.2012.01.026
M3 - Article
C2 - 22309680
AN - SCOPUS:84862814679
SN - 0009-8981
VL - 413
SP - 861
EP - 868
JO - Clinica Chimica Acta
JF - Clinica Chimica Acta
IS - 9-10
ER -